AU2001269688A1 - Combination containing an antifolate and methylmalonic acid lowering agent - Google Patents

Combination containing an antifolate and methylmalonic acid lowering agent

Info

Publication number
AU2001269688A1
AU2001269688A1 AU2001269688A AU6968801A AU2001269688A1 AU 2001269688 A1 AU2001269688 A1 AU 2001269688A1 AU 2001269688 A AU2001269688 A AU 2001269688A AU 6968801 A AU6968801 A AU 6968801A AU 2001269688 A1 AU2001269688 A1 AU 2001269688A1
Authority
AU
Australia
Prior art keywords
antifolate
lowering agent
methylmalonic acid
acid lowering
combination containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001269688A
Inventor
Clet Niyikiza
Paolo Paoletti
James Jacob Rusthoven
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27396105&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2001269688(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2001269688A1 publication Critical patent/AU2001269688A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

A method of administering an antifolate to a mammal in need thereof, comprising administering an effective amount of said antifolate in combination with a methylmalonic acid lowering agent.
AU2001269688A 2000-06-30 2001-06-15 Combination containing an antifolate and methylmalonic acid lowering agent Abandoned AU2001269688A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US21531000P 2000-06-30 2000-06-30
US60/215,310 2000-06-30
US23585900P 2000-09-27 2000-09-27
US60/235,859 2000-09-27
US28444801P 2001-04-18 2001-04-18
US60/284,448 2001-04-18
PCT/US2001/014860 WO2002002093A2 (en) 2000-06-30 2001-06-15 Combination containing an antifolate and methylmalonic acid lowering agent

Publications (1)

Publication Number Publication Date
AU2001269688A1 true AU2001269688A1 (en) 2002-01-14

Family

ID=27396105

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001269688A Abandoned AU2001269688A1 (en) 2000-06-30 2001-06-15 Combination containing an antifolate and methylmalonic acid lowering agent

Country Status (11)

Country Link
US (4) US7053065B2 (en)
EP (1) EP1313508B1 (en)
JP (7) JP5102928B2 (en)
AT (1) ATE359823T1 (en)
AU (1) AU2001269688A1 (en)
CY (1) CY1107649T1 (en)
DE (1) DE60127970T2 (en)
DK (1) DK1313508T5 (en)
ES (1) ES2284660T3 (en)
PT (1) PT1313508E (en)
WO (1) WO2002002093A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002002093A2 (en) * 2000-06-30 2002-01-10 Eli Lilly And Company Combination containing an antifolate and methylmalonic acid lowering agent
ES2417065T3 (en) 2005-04-26 2013-08-05 Trion Pharma Gmbh Combination of antibodies with glucocorticoids for cancer treatment
JP2009523149A (en) * 2006-01-12 2009-06-18 ノバルティス アクチエンゲゼルシャフト Combination of mTOR inhibitor and antifolate compound
WO2010021843A1 (en) * 2008-08-20 2010-02-25 Eli Lilly And Company Use of antifolates in patients with detectable levels of tff-1 for the cancer treatment
US8501242B2 (en) 2009-05-29 2013-08-06 University Of Florida Research Foundation Methods and compositions for treating neoplasia
WO2012088282A1 (en) 2010-12-21 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of pemetrexed-based compounds
EP3210629A1 (en) 2012-05-30 2017-08-30 Fresenius Kabi Oncology Ltd Pharmaceutical composition of pemetrexed
WO2015187089A1 (en) 2014-06-04 2015-12-10 Thomas Helledays Stiftelse För Medicinsk Forskning Mth1 inhibitors for treatment of inflammatory and autoimmune conditions
US10531957B2 (en) 2015-05-21 2020-01-14 Musculoskeletal Transplant Foundation Modified demineralized cortical bone fibers
JP6768786B2 (en) * 2015-07-30 2020-10-14 エクスプレッション、パソロジー、インコーポレイテッドＥｘｐｒｅｓｓｉｏｎ Ｐａｔｈｏｌｏｇｙ， Ｉｎｃ． Quantification of FR-α and GART proteins for optimal cancer therapy
IL290251B1 (en) * 2015-12-07 2024-03-01 General Oncology Inc Combination for the effective treatment of metastatic cancer in patients
CA3033077A1 (en) 2016-08-12 2018-02-15 L.E.A.F. Holdings Group Llc Alpha and gamma-d polyglutamated antifolates and uses thereof
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
CA3049435A1 (en) 2017-01-09 2018-07-12 Scott Grindrod Selective histone deacetylase inhibitors for the treatment of human disease
CN112004537A (en) 2018-01-09 2020-11-27 穿梭药业公司 Selective histone deacetylase inhibitors for the treatment of human diseases
CA3090494A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated pemetrexed and uses thereof
WO2019157129A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated pralatrexate and uses thereof
JP7442822B2 (en) * 2018-02-14 2024-03-05 エル．イー．エー．エフ． ホールディングス グループ エルエルシー γ-polyglutaminated tetrahydrofolic acid and its uses
EP3752157A4 (en) 2018-02-14 2022-07-06 L.E.A.F Holdings Group LLC Gamma polyglutamated lometrexol and uses thereof
WO2023177894A1 (en) 2022-03-18 2023-09-21 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and an antimetabolite agent

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US216350A (en) * 1879-06-10 Improvement in car-replacers
US225030A (en) * 1880-03-02 Rotary engine
US2920015A (en) * 1957-08-27 1960-01-05 Armour & Co Long-acting vitamin b12
CH605550A5 (en) * 1972-06-08 1978-09-29 Research Corp
US5563126A (en) 1986-11-20 1996-10-08 Metabolite Laboratories Method for treatment and prevention of deficiencies of vitamins B12, folic acid, and B6
JP2962755B2 (en) * 1989-02-28 1999-10-12 帝人株式会社 Novel Vitamin B (lower 1) (lower 2) derivative, its production method and its use
US5405839A (en) * 1989-02-28 1995-04-11 Teijin Limited Vitamin B12 derivative, preparation process thereof, and use thereof
KR0162654B1 (en) * 1989-12-11 1998-11-16 알렌 제이. 시니스갤리 N-[pyrrolo (2, 3-d) pyrimidin-3yl acryl]-glutamic acid derivatives
DE69112376T3 (en) * 1991-03-29 2002-08-14 Lilly Co Eli Improved therapy method.
JPH05163160A (en) * 1991-12-13 1993-06-29 Snow Brand Milk Prod Co Ltd Nutrient preparation for prevention and treatment of infectious disease caused by immune depression
US6207651B1 (en) 1996-08-02 2001-03-27 Metabolite Laboratories Method for treatment and prevention of deficiencies of vitamins B12, folic acid, and B6
CA2187346C (en) 1994-04-08 2010-06-29 A. Charles Morgan, Jr. Receptor modulating agents and methods relating thereto
WO1996012181A1 (en) 1994-10-12 1996-04-25 Research & Diagnostics Systems, Inc. Reticulocyte assay control
WO2002002093A2 (en) * 2000-06-30 2002-01-10 Eli Lilly And Company Combination containing an antifolate and methylmalonic acid lowering agent
US20040005311A1 (en) * 2001-07-20 2004-01-08 Pitman Bradford D. Dietary supplement compositions

Also Published As

Publication number Publication date
ES2284660T3 (en) 2007-11-16
WO2002002093A2 (en) 2002-01-10
WO2002002093A3 (en) 2003-02-06
JP5469706B2 (en) 2014-04-16
DE60127970D1 (en) 2007-05-31
DK1313508T5 (en) 2017-03-20
US7772209B2 (en) 2010-08-10
EP1313508B1 (en) 2007-04-18
EP1313508A2 (en) 2003-05-28
US20030212038A1 (en) 2003-11-13
DE60127970T2 (en) 2007-12-20
JP2012180381A (en) 2012-09-20
JP2020117536A (en) 2020-08-06
JP5102928B2 (en) 2012-12-19
US20100210583A1 (en) 2010-08-19
JP2018197265A (en) 2018-12-13
ATE359823T1 (en) 2007-05-15
CY1107649T1 (en) 2013-04-18
US20060079480A1 (en) 2006-04-13
JP2014005304A (en) 2014-01-16
JP2017019852A (en) 2017-01-26
US7053065B2 (en) 2006-05-30
DK1313508T3 (en) 2007-08-06
JP2015178501A (en) 2015-10-08
PT1313508E (en) 2007-06-21
US20080032948A1 (en) 2008-02-07
JP2004501964A (en) 2004-01-22

Similar Documents

Publication Publication Date Title
AU2001269688A1 (en) Combination containing an antifolate and methylmalonic acid lowering agent
WO2001068138A3 (en) Intradermal-penetration agents for topical local anesthetic administration
AU2002245302A1 (en) Methods of using and compositions comprising sibutramine metabolites optionally in combination with other pharmacologically active compounds
BR9812289A (en) Combination of catamenial plug and inserter and production process
AU3104301A (en) Compositions and methods to effect the release profile in the transdermal administration of active agents
WO2002005800A3 (en) Compositions for sustained release of analgesic agents, and methods of making and using the same
AU2001286578A1 (en) Topical antioxidant having vitamin c and method of combination with topical agent by user
AU5905400A (en) Methods and compositions for delivery and retention of active agents to lymph nodes
IL160109A0 (en) Topical pharmaceutical formulation
NZ516349A (en) Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
MXPA03002207A (en) 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors.
AU2603400A (en) Formulations for treating disease and methods of using same
EP1458870A4 (en) COMPOSITIONS AND PROCESSES USING siRNA, AMPHIPATHIC COMPOUNDS AND POLYCATIONS
AU2002210575A1 (en) Novel medicament compositions based on anticholinergics and corticosteroids
AU7914600A (en) The use of baclofen in the treatment of alcohol withdrawal syndrome and to promote alcohol abstinence in alcoholics
IS6581A (en) A combination that increases mobility
WO2001085188A3 (en) Use of echinacea as a hematinic agent
WO2001043748A3 (en) Implant composition containing melengestrol acetate and trenbolone acetate
AUPQ866500A0 (en) Therapeutic compounds and methods
ZA200301459B (en) Infusion of ciprofloxacin having reduced acid content and being stable in storage.
AU4874301A (en) Medicinal compositions containing camptothecin derivative and ph regulating agent
AU4193800A (en) Use of tagatose to enhance key blood factors
WO2002022558A3 (en) 2-amino-2-alkyl-3 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
WO2002022557A3 (en) 2-amino-2-alkyl-4 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
WO2003053353A3 (en) Administration of vasopeptidase inhibitors to reduce pulse pressure